Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

Oculis S.A.

Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery to the eye. Oculis has developed the solubilizing nanoparticle (SNP) drug delivery platform consisting of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The SNP platform provides sustained release over several hours and allows for greatly increased solubility of lipophilic drugs. Among the key advantages of the SNP platform is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application, i.e. an eye drop. *

 

Period Start 2019-01-04 existent
  Group Oculis (Group)
Products Industry solubilizing nanoparticle (SNP) drug delivery platform (Oculis)
  Industry 2 OC-118 (Oculis)
Persons Person Sherif, Riad (Oculis 201801– CEO before Novartis Area President EMEA at Alcon)
  Person 2 Jóhannesson, Páll Ragnar (Oculis 201801– CFO Oculis SA + Managing Director Oculis ehf before CEO Oculis)
     
Region Region Lausanne VD
  Country Switzerland
  Street EPFL Innovation Park, Building C
EPFL Innovation Park, Building C
  City 1015 Lausanne VD
  Tel +41-21-711-3970
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Oculis ehf.. (8/11/16). "Press Release: Oculis Completes Series A Financing". Reykjavik.
     
   
Record changed: 2021-05-11

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Oculis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture [iito] Back into Ad 650x80px




» top